Hip Arthroplasty
Conditions
Interventions
Case series:None
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
Female
Age
60 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Age =60, =75 years, female; 2) BMD of lumbar spine or hip (assessed by QCT or DXA): -4.0 < T = -2.5; 3) Hip diseases such as femoral neck fracture, osteoarthritis of the hip or necrosis of the femoral head. 3) Patients who need to undergo total hip replacement due to hip diseases such as femoral neck fracture, osteoarthritis of the hip or necrosis of the femoral head; 4) The surgical prosthesis is to be a bioprosthesis; 5) Patients who are going to receive basic treatment with deslumizumab or bisphosphonates or only basic treatment; 6) Patients who voluntarily sign an informed consent form
Exclusion criteria
Exclusion criteria: 1) Patients with contraindications to total hip arthroplasty; 2) malignant tumors, bone infections, Paget's disease of bone or other endocrine diseases that cannot be controlled by medical therapy or other diseases that have a serious effect on bone metabolism (e.g. hyperparathyroidism, hyperparathyroidism, etc.); 3) Contraindications to the use of deslizumab, such as hypocalcemia, hypersensitivity to the active ingredient or to any of the excipients; 4) Patients who have received anti-osteoporosis treatment with deslumizumab, teriparatide or romozolomide within 12 months prior to enrollment; 5) Patients who intend to receive other anti-osteoporotic therapy such as teriparatide or romozolomide during the study period; 6) Patients who are assessed by the investigator to be unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Osteointegration rate of prosthesis at 12 months postoperatively; | — |
Secondary
| Measure | Time frame |
|---|---|
| Bone density at 6 and 12 months after surgery;Prosthesis loosening rate at 3, 6, and 12 months postoperatively;Height of prosthesis subsidence at 3, 6 and 12 months after surgery;Bone turnover indexes at 3, 6, and 12 months after surgery;Postoperative Harris score at 3, 6, 12 months;WOMAC arthritis score at 3, 6, and 12 months after surgery;Electrolyte levels;Adverse Events; | — |
Countries
China
Contacts
Public ContactZhang Bin
The First Affiliated Hospital of Nanchang University
Outcome results
None listed